Cargando…
Reviewing the Pathophysiology Behind the Advances in the Management of Giant Cell Arteritis
Improving understanding of the underlying pathophysiology of giant cell arteritis (GCA) is transforming clinical management by identifying novel avenues for targeted therapies. One key area of concern for both clinicians and patients with GCA is glucocorticoid (GC) morbidity. The first randomised co...
Autores principales: | Al-Mousawi, Alia Z., Gurney, Sam P., Lorenzi, Alice R., Pohl, Ute, Dayan, Margaret, Mollan, Susan P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513947/ https://www.ncbi.nlm.nih.gov/pubmed/30820767 http://dx.doi.org/10.1007/s40123-019-0171-0 |
Ejemplares similares
-
Giant cell arteritis: reviewing the advancing diagnostics and management
por: Bilton, Edward J., et al.
Publicado: (2023) -
Profile of tocilizumab and its potential in the treatment of giant cell arteritis
por: Mollan, Susan Patricia, et al.
Publicado: (2018) -
Giant cell arteritis complicated by acute pancreatitis: a case report
por: Seneviratne, Deepthi Renuka, et al.
Publicado: (2008) -
Response to ‘Comment on: ‘A new era for giant cell arteritis’’
por: Mollan, S. P., et al.
Publicado: (2019) -
European Headache Federation recommendations for neurologists managing giant cell arteritis
por: Mollan, S. P., et al.
Publicado: (2020)